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Abstract
Etoposide phosphate (EP), a water-soluble anticancer prodrug, is widely used for treatment of 
many cancers. After administration it is rapidly converted to etoposide, its parent compound, 
which exhibits anticancer activity. Difficulty in parenteral administration necessitates the 
development of a suitable nanoparticle delivery system for EP. Here we have used indium both as 
a carrier to deliver etoposide phosphate to tumor cells and as a SPECT imaging agent through 
incorporation of 111In. Etoposide phosphate was successfully encapsulated together with indium in 
nanoparticles, and exhibited dose dependent cytotoxicity and induction of apoptosis in cultured 
H460 cancer cells via G2/M cell cycle arrest. In a mouse xenograft lung cancer model, etoposide 
phosphate/indium nanoparticles induce tumor cell apoptosis, leading to significant enhancement of 
tumor growth inhibition compared to the free drug.
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Introduction
Etoposide, an analog of the anti-cancer agent podophilotoxin, is clinically used for the 
treatment of several cancers including lung cancer and testicular cancer.1 The mechanism of 
its anti-cancer activity involves inhibition of topoisomerase II, an enzyme responsible for 
DNA strand ligation during cell division. Cancer cells rely on this enzyme to a greater extent 
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than healthy cells because of their rapid growth.2 Etoposide forms a complex with DNA and 
topoisomerase II and prevents re-ligation of the DNA strand, resulting in strand breakage 
and subsequent apoptosis. Due to the limited solubility of etoposide, a water soluble prodrug 
named Etoposide phosphate (EP) was synthesized.3 EP is readily metabolized in vivo to its 
parent molecule, Etoposide, for anticancer activity.3-5 Although administration of EP 
resolved the solubility issue, parenteral administration of EP frequently causes leukopenia 
and neutropenia in patients. These adverse effects underscore the need for a nanoparticle 
delivery system to carry EP to the appropriate cells after systemic administration.
Over the past few decades, there have been major diagnostic and therapeutic advances in 
cancer nano medicine.6 Nanoparticles can extravasate through leaky tumor vasculature and 
preferentially accumulate in tumor tissue due to the enhanced permeability and retention 
(EPR) effect.7, 8 A number of nanoparticle systems based on liposomes, polymers, inorganic 
materials, etc. have been developed for delivery of anticancer drugs and imaging agents to 
tumors. The subject has been recently reviewed.9
Previous reports have demonstrated in vitro delivery of etoposide using different 
nanoparticle formulations, including single-walled nanotubes modified with epidermal 
growth factor,10 strontium carbonate,11 lipid nano capsules (LNC)12 and other polymer-
based nanoparticles.13-16 In a recent study, intra-tumoral injection of etoposide encapsulated 
in poly (ethylene glycol)-co-poly (sebacic acid) (PEG-PSA) polymeric nanoparticles 
exhibited significant antitumor activity compared to control in an NCI-H82 xenograft mouse 
model,17 but this intra-tumoral route of administration has not been established as an 
alternative in routine clinical practice.
Transition metal cations like indium readily precipitate phosphorylated compounds at 
neutral pH, and we found that EP could be readily precipitated by InCl3. We took advantage 
of the In-EP complex and used this nanoprecipitate to deliver EP to tumor cells. This 
manuscript describes the first time an indium-based nanoparticle drug delivery system has 
been reported for EP. Because a radioactive isotope of indium, 111In, is also an excellent 
contrast agent for diagnostic imaging by single photon emission computed tomography 
(SPECT), this complex was also used as a theranostic agent.18-21
In the present manuscript, we propose the synthesis of a nano-sized, lipid-stabilized indium-
EP complex using a reverse micro emulsion system. The surface of the nanoparticles was 
highly PEGylated to increase dispersion during fabrication and stability in circulation and 
reduce nonspecific uptake by the mononuclear phagocyte system (MPS). Here, we 
characterize the in vitro and in vivo performance of these nanoparticles.
Experimental
Materials
Etoposide phosphate was purchased from Carbosynth (UK), 2-Dioleoyl-3-
trimethylammoniumpropanechloride salt (DOTAP), dioleoylphosphatydic acid (DOPA), 
and 1,2-distearorylsnglycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol-2000) ammonium salt (DSPE-PEG2000) were purchased 
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from Avanti Polar Lipids, Inc. (Alabaster, AL). All other chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO) unless otherwise mentioned.
Cell culture
H460 human NSCLC cells, obtained from American Type Culture Collection (ATCC), were 
cultured in an RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin (Invitrogen). Cells were 
cultivated in a humidified incubator at 37°C and 5% CO2.
Experimental animals
Female nude mice and CD-1 mice of 6-8 weeks age were purchased from National Cancer 
Institute (Bethesda, MD) and bred in the Division of Laboratory Animal Medicine (DLAM) 
at University of North Carolina at Chapel Hill. To establish the xenograft models, 5×106 
cells in 50 μL of PBS were injected subcutaneously into the right flank of the mice. All work 
performed on animals was approved by the Institutional Animal Care and Use Committee at 
the University of North Carolina at Chapel Hill.
Preparation of Etoposide phosphate loaded Indium nanoparticles (IEP-PEG)
The IEP core particles were prepared as reported previously with some modifications.22 
Two hundred and fifty μL of 20 mM etoposide phosphate solution was added to 20 mL oil 
phase containing a cyclohexane/IgepalCO-520/triton-100/Hexanol solution 
(71.25/22.5/3.75/2.5, v/v) with continuous stirring. Another micro emulsion was prepared by 
adding 250uL of 100 mM Indium chloride in water to 20ml of the described oil phase. 300 
μL of DOPA (25mg/mL) solution was added to the oil phase containing EP. After five 
minutes, two separate micro-emulsions were mixed and stirred continuously for 20 min 
before the addition of 40 mL of absolute ethanol. The resultant solution was centrifuged at 
10000 × g for 20 min to pellet the IEP core, and the supernatant was removed. This washing 
procedure was repeated twice to remove any excess surfactant. The remaining precipitate 
was dissolved in chloroform and centrifuged once again at 10000 × g for 5 min to remove 
any non DOPA-coated precipitate. The DOPA-coated core particles dissolved in chloroform 
could then be stored at −20°C for at least 1 month before use. The final particles were made 
by adding 20mM DOPC, Chol and DSPE-PEG (1:1:0.5 mole ratios) dissolved in chloroform 
to the IEP cores. The ratio of total outer leaflet lipid volume to total oil phase volume is 
0.044:1. The solvent was then removed under reduced pressure to form a dry lipid film. The 
final particles were prepared by hydration with 80°C water and sonication.
Characterization of IEP-PEG nanoparticles
Transmission electron microscope (TEM) images of IEP core particles were acquired by 
JEOL 100CX II TEM (Tokyo, Japan). The Energy dispersive X-ray spectroscopy (EDS) 
results were obtained by JEOL 2010F FaSTEM, 200kV accelerating voltage connected to 
Oxford X-mas system. A 300 mesh carbon coated copper grid (Ted Pella, Inc., Redding, 
CA) was used to prepare samples for TEM and EDS. The particle size and zeta potential of 
final, lipid coated IEP-PEG nanoparticles were determined by dynamic light scattering 
(DLS) using a Malvern ZetaSizer Nano series (Westborough, MA). Encapsulation efficiency 
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(EE) of EP was measured by a UV/Vis spectrophotometer (Beckman Coulter Inc., DU 800). 
The mass spectrum was obtained using LCMS (Shimadzu).
In vitro cellular uptake of IEP-PEG
Cellular uptake of IEP-PEG nanoparticles by H460 cancer cells was observed by using dual 
labeled nanoparticles. The particle cores were labeled with NBD-DOPA and lipid bilayer 
was labeled with DiI. The labeled particles were incubated with cells for 4 h, washed twice 
with PBS, and fixed with 4% paraformaldehyde. Nuclei were stained with DAPI (Vector 
laboratories, CA). Fluorescent pictures were taken using an Olympus FV1000 MPE SIM 
Laser Scanning Confocal Microscope (Olympus).
In vitro release of IEP-PEG—The in vitro release of EP from IEP-PEG was measured in 
triplicate at two different pH levels of PBS: pH 7.4 and pH 5. Approximately 150 nmol of 
EP in IEP-PEG was diluted to 200ul in water and was added to 300 μl of PBS in the upper 
chamber of a Slide-A-Lyzer dialysis tube, MW cutoff 3.5kDa. The lower chamber was filled 
with 14 ml of PBS to act as a sink condition, and the entire apparatus was shaken at 120 
RPM and 37°C. At t = 0.5, 1, 2, 4, 8, 16, 24, and 48 h, the lower chamber was emptied into 
another vial and replaced with fresh PBS. At the end of the study, all samples were 
lyophilized and re suspended in 400 μl of water. The UV absorption of each sample was 
then read and compared against an EP standard curve (max Abs = 288 nm) to reconstruct the 
release profile.
In vivo pharmacokinetics and bio-distribution
111IEP-PEG nanoparticles were fabricated by mixing a trace amount of 111In (111InCl3, 
PerkinElmer, Inc.) with the EP aqueous phase just before its addition to the microemulsion. 
In vivo pharmacokinetics of 111IEP-PEG were conducted by injecting 111IEP-PEG i.v. into 
the mouse tail vein, extracting a small volume of blood at several time points, and reading 
the signal from 111In using gamma scintillation. Bio-distribution of 111IEP-PEG 
nanoparticles was also measured in H460 tumor-bearing nude mice after i.v. injection 
of 111IEP-PEG. 2 h or 24 h after injection, mice were sacrificed, their organs were dissected, 
and the 111In signal in each organ was read. In addition, one mouse was given a dose of ~1.1 
mCi of 111IEP-PEG and the bio-distribution in the live mouse was measured at t= 2h using 
SPECT imaging.
In vitro cell viability assay (MTT)
In vitro cell viability of IEP-PEG nanoparticles was determined by using the 3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay. H460 cells were 
seeded at a density of 1×104 per well in 96-well plates 24 h prior to treatment. The cells 
were incubated with different concentrations of IEP-PEG, free InCl3, free outer liposome 
and free etoposide phosphate in serum free Opti-MEM (Gibco) media, after four hours the 
medium was replaced with complete medium (RPMI1640 + 10% FBS), The concentrations 
of InCl3 and free liposomes were maintained in equal amounts used for IEP-PEG. After 36 
h, the medium was replaced with fresh medium containing 5% MTT (Biosynth Inc.) solution 
and incubated at 37 °C for another 4h. The resulting formazan crystals were solubilized by 
adding 100 μL DMSO/Methanol (50:50) solution to each well. The absorbance at 570 nm 
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was measured with a micro plate reader. Cell viability was calculated as the (absorbance of 
treated cells)/(absorbance of untreated cells)*100%.
Caspase activation assay
H460 cells (2×105) were treated with nanoparticles containing 25 μM EP, or with relevant 
controls for 4h in serum free Opti-MEM, after which the medium was replaced with 
complete medium containing RPMI 1640 with 10% FBS. After 36 h, the cells were lysed 
with a radio-immunoprecipitation assay (RIPA) buffer that was supplemented with a 
protease inhibitor cocktail (Promega, Madison, WI). The protein lysates were collected by 
centrifugation at 14,000 rpm for 10 min at 4°C. Protein concentrations were determined 
using the BCA assay kit (Pierce Biotechnology) following the manufacturer's 
recommendations. Thirty micrograms protein of each sample was used to detect caspase-3/7 
activity of the cell lysates by using an in vitro assay kit according to the manufacturer's 
instructions (Promega).
Western blot analysis for PARP
Forty micrograms of protein per lane, prepared as in the above section, was resolved by 
4-12% SDS-PAGE Electrophoresis (Invitrogen) before being transferred to 
polyvinylidenedifluoride (PVDF) membranes (Bio-Rad). The membranes were blocked for 
1 h with 5% skim milk at room temperature and then incubated with a mouse monoclonal 
poly (ADPribose) polymerase-1 (PARP-1) antibody (1:500 dilution; Santa Cruz 
biotechnology, Inc.) and with a β-actin antibody (1:4,000 dilution; Santa Cruz 
biotechnology, Inc.) overnight at 4°C. β-actin was probed as the loading control. The 
membranes were washed 3 times and then incubated with a secondary antibody (1:4,000 
dilutions; Santa Cruz biotechnology, Inc.) at room temperature for 1 h. Goat anti-mouse 
secondary antibody was used for PARP and β-actin primary antibody. The membranes were 
washed 4 times and developed by an enhanced chemiluminescence system according to the 
manufacturer's instructions (Thermo scientific).
Cell cycle analysis
2×105 H460 cells were seeded in 6-well plates 24h prior to treatment with nanoparticles 
containing 25 μM EP, or with relevant controls in serum-free Opti-MEM for four h, after 
which the media was replaced with RPMI1640 + 10% FBS. The cells were then incubated 
for 24 h at 37 °C in a humidified CO2 incubator. The cells were trypsinized and washed with 
PBS, followed by fixation in pre-cooled 70% ethanol at −20 °C for >1 h. Fixed cells were 
washed with PBS staining buffer (BD Pharmingen, San Diego, CA) and incubated with 
RNAase (final concentration 75 mg/mL) at 37 °C for 30 min, followed by incubation with 
10 mg propidium iodide (PI) at room temperature for 30 min. Finally, cells were washed and 
suspended in PBS, and analyzed with a FACS Canto flow cytometer (BD Biosciences) to 
measure the PI intensity, which correlates with the DNA content in the cell cycle. A total of 
20,000 events were acquired for each sample and data were analyzed with FACS Diva 
software (BD Biosciences).
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Tumor growth inhibition studies
A tumor growth inhibition study was completed on H460 subcutaneous xenograft mouse 
models. Mice were inoculated with 5×106 H460 cells by subcutaneous injection. Treatment 
was started after the tumor volumes reached ~100-150 mm3 in volume. The mice were 
randomly assigned into treatment groups (n=5), and IEP-PEG or free EP were injected. 
Injections were performed every other day for a total of 4 injections at an EP dose of 5 
mg/kg. Tumor sizes were measured every other day with calipers across their two 
perpendicular diameters, and the tumor volume was calculated using the following formula: 
V=0.5 × (W×W×L), where V is tumor volume, W is the smaller perpendicular diameter and 
L is the larger perpendicular diameter. Body weight of each mouse was recorded every other 
day to assess any toxicity.
TUNEL and Immunohistochemistry Assay
In vivo tumor cell apoptosis was determined by TdT-mediated dUTP Nick-End Labeling 
(TUNEL) assay. H460 tumor bearing mice were given three daily IV injections of IEP-PEG 
or free EP at a dose of 5 mg/kg (n=3). Twenty-four hours after the final injection, mice were 
sacrificed and tumors were fixed in 4% paraformaldehyde solution for 12 h before being 
embedded in paraffin and sectioned at a thickness of 5 μm. The TUNEL staining was 
performed as recommended by the manufacturer (Promega). DAPI mounting medium 
(Vector Laboratories, Inc., Burlingame, CA) was dropped on the sections for nuclear 
staining. Images of TUNEL-tained tumor sections were obtained by using a fluorescence 
microscope (Nikon Corp., Tokyo, Japan). The percentage of apoptotic cells was obtained by 
dividing the number of apoptotic cells (TUNEL positive cells shown as green dots) by the 
number of total cells (blue nuclei stained by DAPI, not shown) in each microscopic field, 
and 10 representative fields were randomly selected in each treatment group for this 
analysis. Proliferation of tumor cells after the aforementioned treatments and dosing 
schedule was detected by immunohistochemistry, using an antibody against proliferating 
cell nuclear antigen (PCNA) (1:200 dilution, Santa Cruz). The immunohistochemistry was 
performed using a mouse-specific HRP/DAB detection IHC kit as recommended by the 
manufacturer (Abcam, Cambridge, MA). The percentage of proliferating cells was obtained 
by dividing the number of PCNA positive cells (shown as brown dots) by the number of 
total cells (blue nuclei stained by hematoxylin) in each microscopic field, and 10 
representative microscopic fields were randomly selected in each treatment group (n=3) for 
quantification.
In vivo safety studies
CD-1 mice were intravenously treated with 5 mg/kg IEP-PEG particles every other day for a 
total of three injections. One day after the third injection, mice were sacrificed and organs 
were collected and fixed in 4% paraformaldehyde solution followed by H&E staining. The 
pictures were taken using a bright field microscope (Nikon, Japan).
Statistical analysis
Results were expressed as a mean ± standard deviation (SD) and were compared among 
different groups using Student's t-test. P< 0.05 was considered as statistically significant.
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Characterization of IEP-PEG nanoparticles
Indium and etoposide phosphate were precipitated in a reverse micro emulsion as described 
above to generate the IEP nanoparticle cores, which were analyzed using high resolution 
TEM to evaluate their morphology and size. Stable cores could be fabricated as small 
nanoparticles with a diameter of only ~5 nm. Energy dispersive X-ray spectroscopy (EDS) 
confirmed the presence of indium and phosphate in the cores (Fig. 1A). The amount of 
etoposide phosphate (EP) encapsulated in the DOPA-stabilized IEP core was measured by 
UV-Vis spectroscopy (Fig. 1B) by using a standard curve for free EP. Using this method, we 
found that 60-65% of the drug was encapsulated in the nanoparticles. The structure of EP 
from lysed IEP nanoparticles was analyzed by ESI-MS (Fig. 1C) and showed that free and 
nanoparticle-associated EP had similar mass, confirming that the structure of the drug was 
not changed by the nanoparticle preparation process (data not shown). Final particles were 
generated by coating the cores with DOPC, cholesterol, and DSPE-PEG2000 to form an 
outer leaflet for the lipid bilayer, lengthen time in circulation, and enhance tumor 
accumulation. After lipid film hydration, TEM images show that the small particle cores 
aggregate to form slightly larger particle conglomerates with an average size of ~55nm as 
calculated by TEM (Fig. 1D) and dynamic light scattering (DLS) (Fig. 1E). Using DLS, the 
zeta potential was −40 mV for the final IEP-PEG particles (Fig. 1F).
In vitro cellular uptake of IEP-PEG
The unorthodox final particle structure necessitated confirmation that these particles could 
indeed enter into tumor cells. IEP-PEG was dual-labeled with NBD-DOPA (green) to show 
successful inner leaflet lipid coating during core formation, and also with the small molecule 
DiI (red) to show the presence of a lipid bilayer in the final particle. IEP-PEG was incubated 
with H460 cells in vitro for 4 h before washing and fixing the cells for analysis. Fig. 2 shows 
that both DiI and NBD accumulate in cells, suggesting that the IEP-PEG particles are able to 
enter the cells intact.
In vitro release and anti-cancer activity of IEP-PEG nanoparticles
The release profile of IEP-PEG was measured to determine the stability of the particles in 
PBS at a pH of 7.4 and 5.0. The release profile showed a slow, steady release of drug with 
no burst release (Figure 3A). This release was not acid sensitive, which was not surprising, 
given the low Ksp of phosphate and indium.
The in vitro anti-cancer activity of IEP-PEG nanoparticles was measured by an MTT assay 
in a cultured NCI- H460 lung carcinoma cell line that was incubated with a range of 
formulations for four h before changing the media and incubating for another 36 h. The cells 
experienced a dose-dependent toxicity from IEP-PEG nanoparticles and free EP, but free 
InCl3 and free outer leaflet liposomes did not cause any toxicity (Fig. 3A).
Mechanisms of cell death from 25 μM EP in vitro were also determined. Cells were 
incubated with IEP-PEG and controls for 24 h before collection and measurement. The 
DNA damage caused by EP induces apoptosis through the activity of caspase-type 
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proteases,23 primarily caspases 3 and 7. Compared to the untreated control, the amount of 
these apoptotic caspases in cultured H460 cells was 6-fold higher when treated with IEP-
PEG nanoparticles and 5-fold higher when treated with free EP (Fig. 3B). Indium chloride 
alone had no effect on caspase 3/7 upregulation. Poly ADP ribose polymerase (PARP-1) 
expression was also measured to determine apoptotic mechanisms of EP. PARP-1, a 113 
kDa enzyme involved in DNA repair, is known to be cleaved by caspases into 24 kDa and 
89 kDa fragments during the execution of apoptosis.24 The 89 kDa cleavage product was 
readily detectable in cells treated with IEP-PEG nanoparticles or free etoposide phosphate 
(Fig. 3C), while free indium chloride again presented no toxic effect.
Effect of EP on cell cycle progression
We further evaluated the effect of IEP-PEG nanoparticles on the cell cycle using flow 
cytometry. Etoposide inhibits topoisomerase II, resulting in DNA strand breakage which in 
turn causes cell cycle arrest at late S or early G2/M phase.25 Analysis of cell cycle 
progression using flow cytometry (Fig. 4) demonstrated that 59% of the cells treated with 
IEP-PEG nanoparticles and 47% of cells treated with free EP were arrested at G2/M phase. 
Cells treated with free InCl3 had no discernable effect on cell cycle progression compared to 
the control.
In vivo Bio-distribution of IEP-PEG nanoparticles
After successful in vitro delivery and treatment using IEP-PEG, we analyzed 
pharmacokinetics and bio-distribution of the nanoparticles using the radioisotope. 111In, a 
radioisotope of indium, emits high energy gamma rays that are detectible via gamma 
scintillation and SPECT imaging. 111In was incorporated into IEP by mixing a trace amount 
of 111In with the EP aqueous phase just before particle fabrication. The low concentration 
of 111In could then begin to associate with the bulk EP before nonradioactive indium could 
competitively inhibit 111In encapsulation. Using this method, 111In incorporation into IEP 
was ~50%.
Pharmacokinetic analysis of 111IEP-PEG shows that the particles cleared quickly from 
circulation after i.v. injection. As shown in Fig. 5A and Fig. 5B that the bio-distribution of 
these particles does not change greatly between 2h and 24h after injection. These results 
were also supported by SPECT imaging, which was also used by this theranostic particle to 
show 111IEP-PEG bio-distribution and tumor accumulation (Fig. 5C). While the dose 
of 111In was higher for the SPECT study than for the other bio-distribution studies, the dose 
of EP and of IEP particles remained constant. This was achieved by adding different 
amounts of trace 111In to the particles during fabrication, which can vary the radioloading 
density while maintaining the particle batch size.26
In vivo tumor growth inhibition
We next evaluated the antitumor efficacy of IEP-PEG nanoparticle formulations in a mouse 
H460 xenograft tumor model. Tumor-bearing nude mice were intravenously injected with 
nanoparticles or free EP every other day for a total of four injections. Treatment with IEP-
PEG nanoparticles significantly inhibited tumor growth relative to free EP (Fig. 6). This 
may be due to IEP-PEG's ability to take advantage of the tumor's enhanced permeability and 
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retention, while free EP is easily degradable at physiological pH and may also be cleared 
quickly by the kidneys.27 The body weight of the treated mice did not change significantly 
over the course of the study, suggesting that there was no systemic toxicity as a result of the 
treatment.
IEP-PEG-induced tumor cell proliferation inhibition and apoptosis in vivo
After showing successful tumor growth inhibition, tumor cell apoptosis from this in vivo 
treatment was evaluated by the TUNEL assay. The assay is commonly used to detect 
fragmented DNA in apoptotic cells by using fluorescently labeled dUTP. Upon detection, 
apoptotic cells appear as dots of green fluorescence in tumor sections (Fig. 7, upper panels). 
The percentage of tumor cells that were apoptotic was significantly higher after treatment 
with nanoparticles, but not free drug (Fig. 7A).
Proliferating cell nuclear antigen (PCNA) expression, known to be increased in actively 
proliferating cells, was used to evaluate the extent of cell proliferation in xenograft tumors 
after treatment (Fig. 7, lower panels). PCNA was detected by immunohistochemistry in Fig. 
7B, and while tumor sections from untreated mice or mice given free EP contained 75-80% 
proliferative cells, tumor sections from mice treated with IEP-PEG contained only 10-20% 
proliferative cells. Our nanoparticle system appears to effectively induce apoptosis and 
inhibit cell proliferation within tumors by increasing the bioavailability of systemically 
administered EP.
In vivo safety study
To further test the safety profile of free EP and IEP-PEG, we analyzed the systemic toxicity 
of nanoparticles via histopathology analysis of organs taken from mice treated with EP or 
IEP-PEG nanoparticles (Fig. 8). At those given schedule, there were no indicators of 
significant toxicity observed in organs from mice treated with EP or IEP-PEG when 
compared to those from untreated mice.
Discussion
In the present study, we developed a new, indium-based, theranostic nanoparticle system for 
cancer therapy and imaging. Effective administration of the widely used anticancer drug, 
etoposide, is complicated by limitations stemming from its hydrophobicity, lack of 
solubility, and toxicity. The water-soluble analog, EP, offers some improvement but 
bioavailability and toxicity still remain a problem. Here we used indium both as a carrier for 
EP and as an imaging agent (111In) to allow nanoparticle synthesis of EP in addition to 
enabling SPECT imaging via 111IEP-PEG. Lipid-coated IEP-PEG nanoparticles were 
synthesized using a reverse micro emulsion method and then characterized in terms of shape 
and size. Although etoposide and etoposide phosphate are susceptible to degradation 
through epimerization of the lactone ring 28, our formulation did not alter the EP structure, 
as confirmed by UV and ESI-MS (Fig. 1). Because surface functionality determines the fate 
of circulating nanoparticles in vivo, we modified the nanoparticle surface with PEG, a 
widely-used hydrophilic polymer, to increase particle dispersion during fabrication, allow 
some escape from macrophage phagocyte system (MPS) uptake9 and prolong time in 
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circulation. Cytotoxicity studies in NCI-H460 lung cancer cell lines suggest that these 
nanoparticles efficiently deliver EP to tumor cells and exhibit dose-dependent anti-tumor 
activity at a level similar to the free drug. We believe that after endocytosis, EP is 
dissociated from indium in the sink condition, and the released EP is converted to etoposide 
by intracellular phosphatases to achieve its cytotoxic effects.29 Because no significant 
cytotoxicity was observed from treatment with free InCl3, we suspect that this low dose of 
indium dose may be safe for use.
Anti-cancer effects were also evaluated in an H460 xenograft tumor-bearing mouse model, 
where IEP-PEG nanoparticles exhibited anti-tumor activity in mice (Fig. 6). While free EP 
showed efficacy similar to IEP-PEG in vitro, the in vivo data presented here show that IEP-
PEG outperforms free EP in tumor growth inhibition, apoptotic cell generation, and 
inhibition of cell proliferation without inducing toxicity to normal tissue. The added value of 
IEP-PEG in vivo may be caused by the greater bioavailability of IEP-PEG allowed by the 
tumor's enhanced permeability and retention of nanoparticles in the tumor environment 
relative to small molecules, as bio-distribution and drug release studies show that the IEP 
nanoparticles remain in the tumor after 24h and release the drug slowly. Future work with 
this system will include studies focused on improving pharmacokinetics and specific 
accumulation into tumor cells, such as modifying the composition of the outer leaflet lipids 
and conjugating targeting ligands to the particles.
Conclusions
In conclusion, we have successfully encapsulated the anti-cancer prodrug etoposide 
phosphate using an indium-based theranostic nanoparticle system. In vitro cytotoxicity 
studies and in vivo antitumor experiments reveal the efficacy of this nanoparticle 
formulation for delivery of the anticancer drug EP. 111IEP-PEG was also used as a 
theranostic agent for SPECT imaging, allowing simultaneous delivery of both an imaging 
agent and an anti-cancer drug with a single nanoparticle system.
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Characterizations of IEP nanoparticles; A) EDS spectrum of IEP-PEG nanoparticles; B) 
UV/Vis absorption spectrum comparing free EP and EP dissociated from IEP-PEG 
nanoparticles; C) ESI-MS for EP encapsulated in nanoparticles. D) TEM image of final IEP-
PEG nanoparticles; E) hydrodynamic size of IEP-PEG nanoparticles using DLS; F) Zeta 
potential of IEP-PEG nanoparticles using DLS.
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Cellular uptake of dual-labeled IEP-PEG nanoparticles in H460 cells in vitro. Cell nucleus 
labeled with DAPI; inner leaflet lipids labeled with NBD-DOPA; lipid bilayer labeled with 
DiI.
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In vitro release, cytotoxicity, and mechanistic studies of IEP-PEG nanoparticles in H460 
treated cells; A) etoposide phosphate release from IEP in 37°C PBS at pH 7.4 or pH 5; B) 
MTT assay; C) Caspase activation; D) Western blot for PARP-1 cleavage; data in A-C 
presented as mean ± SD, n=3.
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Analysis of cell cycle arrest via flow cytometry 24 h after treatment with 25 μM EP. EP and 
IEP-PEG both showed inhibition of cell cycle progression at G2/M phase.
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Biodistribution of IEP-PEG: A) Pharmacokinetics of 111IEP-PEG; B) Organ biodistribution 
of 111IEP-PEG 2h (n=2) and 24h (n=3) after treatment; C) SPECT/CT images of 111IEP-
PEG 2h after injection, from left to right: axial, coronal, and saggital views.
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In vivo therapeutic effect of IEP-PEG nanoparticles in a H460 xenograft mouse tumor 
model; A) tumor growth inhibition; B) Body weight change, data represent mean ± SD, n=5; 
*p< 0.005; PBS vs. In/EP-PEG); arrows indicate the injection schedule.
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IEP-PEG nanoparticles triggered tumor cell apoptosis and inhibited cell proliferation: 
Tunnel assay (upper panels) and PCNA analysis (lower); A) Tunnel assay quantification 
*p<0.006 for Free EP vs. In/EP-PEG; B) PCNA *p<0.0001 for Free EP vs. In/EP-PEG, n=3.
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H&E analysis of mouse major organs treated with EP or IEP-PEG nanoparticles shows no 
morphological toxicity associated with the treatment (n=3).
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